|9 Months Ended|
Sep. 30, 2011
On November 4, 2011, the Company announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder ("MDD"). The randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5mg and 5mg, to placebo over an 8-week treatment period. Results from the study did not demonstrate Serdaxin's efficacy compared to placebo measured by the Montgomery-Asberg Depression Rating Scale ("MADRS"). All groups showed an approximate 14 point improvement in the protocol defined primary endpoint of MADRS. All groups had a substantial number of patients who demonstrated a meaningful clinical improvement from baseline. The study showed Serdaxin to be safe and well tolerated. The Company is currently evaluating future plans for its candidate pipeline as well as allocations of resources for the candidates.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.